Pharmadrug Inc. (PHRX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.23 CAD | -275.82% |
| 2022 | -0.06 CAD | 49.0% |
| 2021 | -0.12 CAD | 55.56% |
| 2020 | -0.27 CAD | 58.46% |
| 2019 | -0.65 CAD | -132.14% |
| 2018 | -0.28 CAD | -723.53% |
| 2017 | -0.03 CAD | 98.1% |
| 2016 | -1.79 CAD | -1950.4% |
| 2015 | -0.09 CAD | 83.53% |
| 2014 | -0.53 CAD | 14.52% |
| 2013 | -0.62 CAD | -67.57% |
| 2012 | -0.37 CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.01 CAD | 97.52% |
| 2024 Q2 | -0.00 CAD | 73.08% |
| 2023 Q4 | -0.21 CAD | -408.47% |
| 2023 Q1 | -0.00 CAD | -103.49% |
| 2023 Q2 | -0.01 CAD | -492.86% |
| 2023 Q3 | -0.04 CAD | -397.59% |
| 2023 FY | - CAD | -275.82% |
| 2022 Q3 | -0.01 CAD | 44.17% |
| 2022 Q4 | 0.04 CAD | 540.66% |
| 2022 FY | - CAD | 49.0% |
| 2022 Q1 | -0.01 CAD | -42.86% |
| 2022 Q2 | -0.02 CAD | -171.67% |
| 2021 Q4 | -0.00 CAD | -7.69% |
| 2021 FY | - CAD | 55.56% |
| 2021 Q2 | -0.00 CAD | 41.38% |
| 2021 Q3 | -0.00 CAD | -14.71% |
| 2021 Q1 | -0.01 CAD | 33.33% |
| 2020 Q4 | -0.01 CAD | -74.0% |
| 2020 Q3 | -0.01 CAD | 68.94% |
| 2020 Q2 | -0.02 CAD | -906.25% |
| 2020 Q1 | -0.00 CAD | 96.19% |
| 2020 FY | - CAD | 58.46% |
| 2019 Q3 | -0.01 CAD | 73.06% |
| 2019 FY | - CAD | -132.14% |
| 2019 Q4 | -0.04 CAD | -707.69% |
| 2019 Q2 | -0.02 CAD | -85.58% |
| 2019 Q1 | -0.01 CAD | 43.48% |
| 2018 Q4 | -0.02 CAD | 86.86% |
| 2018 FY | - CAD | -723.53% |
| 2018 Q3 | -0.14 CAD | -357.52% |
| 2018 Q2 | -0.03 CAD | -50.0% |
| 2018 Q1 | -0.02 CAD | -140.0% |
| 2017 Q2 | -0.01 CAD | 30.77% |
| 2017 Q4 | -0.01 CAD | -226.92% |
| 2017 Q3 | -0.00 CAD | 58.73% |
| 2017 FY | - CAD | 98.1% |
| 2017 Q1 | -0.01 CAD | 51.34% |
| 2016 Q3 | -0.06 CAD | 96.41% |
| 2016 Q1 | -0.02 CAD | -160.0% |
| 2016 Q2 | -1.57 CAD | -9964.1% |
| 2016 FY | - CAD | -1950.4% |
| 2016 Q4 | -0.02 CAD | 66.79% |
| 2015 FY | - CAD | 83.53% |
| 2015 Q4 | -0.01 CAD | -150.0% |
| 2015 Q3 | 0.01 CAD | 138.71% |
| 2015 Q2 | -0.03 CAD | 34.74% |
| 2015 Q1 | -0.05 CAD | -127.27% |
| 2014 Q3 | -0.15 CAD | -140.77% |
| 2014 Q1 | -0.12 CAD | 62.5% |
| 2014 FY | - CAD | 14.52% |
| 2014 Q4 | -0.02 CAD | 86.07% |
| 2014 Q2 | -0.06 CAD | 48.08% |
| 2013 Q4 | -0.32 CAD | 13.51% |
| 2013 Q2 | -0.04 CAD | 56.6% |
| 2013 Q1 | -0.09 CAD | -158.75% |
| 2013 FY | - CAD | -67.57% |
| 2013 Q3 | -0.37 CAD | -806.86% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q3 | 0.01 CAD | 129.12% |
| 2012 Q2 | -0.03 CAD | 85.0% |
| 2012 Q1 | -0.19 CAD | 34.48% |
| 2012 Q4 | 0.16 CAD | 1827.71% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q4 | -0.29 CAD | 0.0% |